Sun Pharma Buys Organon & Co. for $11.75 Billion in All-Cash Deal
NEW YORK, April 28 —
Sun Pharma is buying Organon & Co. (OGN) for roughly $11.75 billion in cash, a 24% premium to the pre-deal share price.
- Deal value: ~$11.75bn all-cash, a 24% premium that pushed OGN to a 52-week high
- Organon trades at just 3.6x forward earnings and generated $6.2bn in TTM revenue
- Regulatory approval needed from multiple jurisdictions; closing expected mid-to-late 2026
What Actually Happened
Sun Pharma, India's largest drugmaker, agreed to acquire Organon in what would be one of the biggest cross-border pharma deals this year. The $11.75bn price tag covers Organon's equity plus its heavy debt load, which has dragged on the stock since Merck spun it off in 2021. At roughly 1.9x trailing revenue, Sun isn't paying a growth multiple. It's paying a leverage-discount multiple.
The logic is simple. Sun gets Organon's women's health franchise, its established brands portfolio, and biosimilars pipeline — plus distribution in 150 countries. Sun is lining up a bridge loan for approximately $12bn to fund the deal. For a company built on capital discipline, that is a big swing.
The Catch
A 24% premium sounds generous until you check the starting point. At $13.16 before the deal, Organon was a $6.2bn-revenue company valued like a distressed asset. That 3.6x forward P/E reflected real concerns: a heavy debt burden and Nexplanon's patent cliff. Sun is paying a premium on a deeply discounted stock. Long-term OGN holders who bought at the 2021 spin-off price are still underwater, even with the bump.
Then there's the financing question. A $12bn bridge loan for an Indian pharma company acquiring a U.S.-listed target will draw scrutiny from multiple regulators. Cross-border pharma M&A has gotten slower, not faster. The mid-to-late 2026 closing timeline leaves months of deal-spread risk on the table.
Bottom Line
If you own OGN, the trade is mostly done. Shares have priced in most of the premium. What remains is a bet on deal certainty — the spread between the current price and the offer is your compensation for carrying regulatory risk through year-end. This is now an arbitrage position, not an equity position.
If you don't own OGN, the bigger question is whether Sun Pharma can digest $11.75bn of acquisition without choking on the financing. Watch the deal spread. If it widens, the market is flagging closing risk.
Want a full financial breakdown on Organon? Generate a free Basis Report on OGN here.
Basis Report does not hold positions in securities discussed. This is not investment advice.